{"id":15187,"date":"2021-06-04T09:58:47","date_gmt":"2021-06-04T07:58:47","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15187"},"modified":"2021-06-04T09:58:47","modified_gmt":"2021-06-04T07:58:47","slug":"abbvie-recoit-lapprobation-de-la-commission-europeenne-pour-venclyxto-venetoclax-en-association-avec-un-agent-hypomethylant-pour-les-patients-atteints-de-leucemie-myeloide-aigue","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/abbvie-recoit-lapprobation-de-la-commission-europeenne-pour-venclyxto-venetoclax-en-association-avec-un-agent-hypomethylant-pour-les-patients-atteints-de-leucemie-myeloide-aigue\/","title":{"rendered":"AbbVie re\u00e7oit l&#8217;approbation de la Commission europ\u00e9enne pour VENCLYXTO\u00ae (v\u00e9n\u00e9toclax) en association avec un agent hypom\u00e9thylant pour les patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb."},"content":{"rendered":"<p>L&#8217;approbation est bas\u00e9e sur les donn\u00e9es du programme d&#8217;essais cliniques d&#8217;AbbVie pour VENCLYXTO, y compris l&#8217;essai de phase 3 VIALE-A, qui a montr\u00e9 que les patients trait\u00e9s par VENCLYXTO en association avec l&#8217;azacitidine ont d\u00e9montr\u00e9 des am\u00e9liorations de la survie globale par rapport aux patients trait\u00e9s avec le placebo en association avec l&#8217;azacitidine<sup>1<\/sup>.<\/p>\n<p>L&#8217;approbation est \u00e9galement bas\u00e9e sur les r\u00e9sultats de l&#8217;essai de phase 1b M14-358 qui a montr\u00e9 que les patients trait\u00e9s par VENCLYXTO en association avec l&#8217;azacitidine ou la d\u00e9citabine ont obtenu des taux de r\u00e9mission \u00e9lev\u00e9s<sup>2<\/sup>.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td><em>1 &#8211; DiNardo, C.D., Jonas, B.A., et al. A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax With Azacitidine Vs. Azacitidine In Treatment-Na\u00efve Patients with Acute Myeloid Leukemia Ineligible For Intensive Therapy: The Phase 3 VIALE-A Trial. (2020).<\/em><em>\u00a0<\/em><\/p>\n<p><em>2 &#8211; DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182\/blood-2018-08-868752. <\/em><em>Epub 2018 Oct 25.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>","protected":false},"excerpt":{"rendered":"<p>L&#8217;approbation est bas\u00e9e sur les donn\u00e9es du programme d&#8217;essais cliniques d&#8217;AbbVie pour VENCLYXTO, y compris l&#8217;essai de phase 3 VIALE-A, qui a montr\u00e9 que les patients trait\u00e9s par VENCLYXTO en [&hellip;]<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[442],"class_list":["post-15187","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15187"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15187\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15187"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}